The founding of Altos Labs in January 2022, which launched with a record $3bn in venture capital funding from high-profile backers that reportedly include Amazon founder Jeff Bezos and billionaire entrepreneur Yuri Milner, marked the biggest investment in the longevity industry to date.
With a vision of “transforming medicine through cellular rejuvenation programing” and an impressive collection of biotech leaders and academic researchers working at the firm and even Nobel laureates on its board, the series A investment in Altos is leaps and bounds ahead of other longevity funding rounds. (Also see "Big Names Backers Give Altos $3bn To Pursue Cell Rejuvenation Science" - Scrip, 19 January, 2022.) The nearest runner up is InSilico Medicine’s $225m series C, which completed in June 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?